Jigar Raythatha is listed as an executive officer and director on 5 SEC Form D filings by 3 issuers between Apr 2018 and Jun 2026: Triana Biomedicines, Inc. (Lexington, MA — pharmaceuticals — 2022–2025; $120.1M reported sold to 20 investors), CONSTELLATION PHARMACEUTICALS INC (Cambridge, MA — biotechnology — 2018–2019; $99M reported sold to 30 investors) and Third Rock Ventures VII, L.P. (Boston, MA — pooled investment fund — 2026).
What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 8 years. Across those companies the filings report $219.1M sold in total.
Listed alongside Patrick Trojer (3 shared filings), Anthony Evnin (2 shared filings), David Grayzel (2 shared filings), Emma Reeve (2 shared filings), James E. Audia (2 shared filings) and 22 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jigar. Each name links to their own page.
2 of the issuers belong to the sponsor group Third Rock (7 issuers, $2.62B reported sold, 2010–2026).
What this means A sponsor group is one team that sets up a new company for each deal. Third Rock has 7 companies on file and $2.62B reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 5 public filings for Jigar Raythatha and found 4 differences: Offering amount changed between filings; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.